Zentiva ks specializes in the development, manufacture and marketing of generic pharmaceutical products. It offers generic drugs, over the counter medicines, dietary supplements, cosmetics and pharmaceutical substances. The company's products cover therapy areas of cardiovascular disease, pain, alimentary, genitourinary tract diseases, inflammations and central nervous system diseases including digestive problems. Zentiva was founded in 1989 and is headquartered in Prague, Czech Republic.

AstraZeneca is an innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines that are innovative, effective, and which offer added benefits such as reduced side effects or better ways of taking the treatment. AstraZeneca focuses on getting the best from every medicine they make by exploring all the ways it can be used or improved. AstraZeneca was established on April 6, 1999, in Cambridgeshire, United Kingdom.

Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company.Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Other businesses including Drug Discovery & Development Solutions and India Branded Pharmaceuticals. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-sterile products through 6 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery & Development Solutions business, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 2 world class research centers in India. Jubilant Life Sciences Limited has a team of around 7,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally.

Sunshine Lake Pharma Co. Ltd., a subsidiary of Shenzhen Dongyangguang Industry Co., Ltd., is a Chinese company. The firm manufactures and supplies pharmaceutical ingredients and drugs. Wen Jia Li has been the CEO since 2021. On December 23, 2022 Shenzhen Dongyangguang Industry Co., Ltd. acquired Sunshine Lake Pharma Co. Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd. for $330.99 million.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Unichem Laboratories Ltd. is a pharmaceutical company, which engages in the manufacturing and marketing of pharmaceutical formulations. The firm offers its products that address relevant therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives, and pain management. It operates through India and Outside India geographical segments. The Outside India segment comprises of United States of America and others. The company was founded by Amrut Mody in 1944 and is headquartered in Mumbai, India.

Jubilant Generics Ltd. engages in the manufacture and export of pharmaceutical products. The company is headquartered in Greater Noida, India.

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Hangzhou Solipharma Co., Ltd. is a company headquartered in China. The firm operates as a pharmaceutical company.

Ruyuan Hec Pharm Co. Ltd., a subsidiary of HEC Pharma Co. Ltd., is a Chinese company located in Shaoguan that manufactures and supplies pharmaceutical products.

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. Its portfolio includes antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterological, anti-allergies, and anti-diabetics. The company was founded by Penaka Venkata Ramprasad Reddy and Kambam Nithyananda Reddy on December 26, 1986 and is headquartered in Hyderabad, India.

Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the manufacture, research and development, and marketing of pharmaceutical drugs. Its products include valsartan, irbesartan, candesartan cilexetil, olmesartan medoxomil, piperaquine phosphate, voriconazole, lansoprazole, rabeprazole sodium, dasatinib, and gefitinib. The company was founded on December 30, 1999 and is headquartered in Zhuhai, China.

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century. With an emphasis on innovation and technology, the company has established a state-of-the-art research facility – Alembic Research Centre (ARC)-including formulation research, and 150-bed bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad. APL is one of the leading players in the industry to have invested about 11% of its turnover in R&D. As a growth strategy, the company has aggressively started investing in the international generics market with successful ANDA and DMF filings. APL has also filings across Canada, Europe, Australia, South Africa & Brazil. The company caters to the rest of the world markets through branded formulation sales. The company aims to explore opportunities in the therapeutic areas such as Dermatology, Oncology, and Injectable Formulations. APL also has also co-promoted a company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders.

Wuhan Langlai Technology Development Co., Ltd., established on 2013-05-06, Business scope includes bioengineering and new medical technology research;Chemical technology development and technology promotion;Technology development in the field of biological expertise,technology transfer,technical consulting;Daily chemical products,cosmetic,Chemical raw materials(except dangerous goods),Drug intermediate(Free of Hazardous Chemicals),chemical reagent(Free of chemical hazards),Laboratory Instrument Sales;Import and export,Technology Import and Export,Agent import and export(Does not contain goods or technologies that are prohibited or restricted from import and export by the state).(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)

DaebongLS Co., Ltd. engages in the manufacturing and distributing of raw materials for pharmaceuticals and cosmetics. It operates through the following business divisions: Cosmetics, Pharmaceuticals, and Food Additives. The Cosmetics division supplies conditioners, emollients, emulsifiers, permanent wave, and solubilizers. The Pharmaceuticals division offers raw materials used to prevent seizures, peptic ulcer, and hypertension. The Food Additives division provides aquacals, ascorbic acids, corn starches, fish, and folic oils. The company was founded by Jong-Ho Park on July 8, 1986 and is headquartered in Incheon, South Korea.

CSPC Ouyi Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products. It manufactures tablets, capsules, granules, small volume parenteral solutions, suspension and oral solutions falling into antibiotics, analgesic and anti-inflammatory, cardiovascular, anesthetic and metabolic categories. The company was founded in 1938 and is headquartered in Shijiazhuang, China.

Foshan Hongtai Drug Research and Development Co., Ltd., established on 2016-07-20, Business scope includes services:pharmaceutical research,Health food science and technology research and food science and technology research and its technology transfer,technical consulting;Sales:Plant extracts,Class I medical device;Engage in the operation of Chinese herbal medicines with valid approval certificates.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Chongqing Langtian Pharmaceutical Co., Ltd., established on 2010-04-21, Business scope includes licensed projects:Production,Sales:API(Clindamycin Palmitate Hydrochloride,Clindamycin Hydrochloride,D-sodium pantothenate,clindamycin phosphate(for export only),Naltrexone(for export only),Methylnaltrexone bromide(for export only));Import and export of goods and technology,Production of Class II Medical Devices,Production of disinfection products for the prevention and control of infectious diseases,Production of hygiene products and single-use medical products(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Production,Sales:Feed additives(folic acid);research and development,Production,Sales:Pharmaceutical Intermediates;Sales:Chemical Products(Free of Hazardous Chemicals);Chemical Product Research,to develop(Free of Hazardous Chemicals),Sales of Class I Medical Devices,Sales of Class II Medical Devices,Production of Class I Medical Devices,Sales of hygiene products and single-use medical products,Sales of industrial textile products,Manufacture of technical textile products(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)